Description
Modified GRF 1-29 is a truncated version of Growth Hormone-Releasing Hormone (GHRH). Unlike full GHRH, Mod GRF 1-29 is a shorter 29-amino-acid peptide with four modified amino acids to enhance stability and resistance to enzymatic breakdown, potentially improving its half-life and pharmacokinetics. Ipamorelin is a synthetic pentapeptide in the growth hormone secretagogue receptor (GHSR) agonist category, believed to activate ghrelin receptors that may trigger growth hormone synthesis. Fragment 176-191 is a short fragment of growth hormone (hGH), often referred to as AOD 9604, and is considered a “fat-burning peptide.”
Chemical Makeup
Molecular Formula
-
Fragment 176-191: C₇₈H₁₂₅N₂₃O₂₃S₂
-
Modified GRF 1-29: C₁₅₂H₂₅₂N₄₄O₄₂
-
Ipamorelin: C₃₈H₄₉N₉O₅
Molecular Weight
-
Fragment 176-191: 1817.12 g/mol
-
Modified GRF 1-29: 3367.9 g/mol
-
Ipamorelin: 711.8 g/mol
Other known titles
-
Modified GRF 1-29: Mod GRF 1-29, CJC-1295 without DAC
-
Ipamorelin: Ipamorelin Acetate, IPA
-
Fragment 176-191: AOD 9604, GH (hGH) lipolytic fragment, Somatostatin (177-191), tyrosyl
Research and Clinical Studies
Lipolytic Action: The peptide in the blend believed to have the strongest fat-breaking potential is Fragment 176-191. In one experimental study with obese murine models presented with this peptide over two weeks, there was a notable reduction in body weight and excess adipose tissue, linked with increased expression of lipolytic receptors and enhanced energy expenditure and fat oxidation.
Pituitary Gland Impact: Reviews of literature suggest that peptides like Mod GRF 1-29 and Ipamorelin may yield physiological changes that include increases in lean body mass, reductions in fat mass, enhanced exercise tolerance and oxygen uptake, improved muscle strength, and potential influence on growth hormone release through receptor pathways in the pituitary gland. Mod GRF 1-29 may interact with GHRH receptors, while Ipamorelin may activate ghrelin receptors, both potentially stimulating growth hormone secretion.
Fat Burning and Clinical Trials: A large trial of Fragment 176-191 over 12 weeks reported average body weight reduction in subjects, alongside improvements in cholesterol profiles and glucose tolerance, suggesting potential metabolic benefits.
Bone Mineralization: Some research indicates Ipamorelin may help increase bone mineral content in experimental models, possibly leading to denser bone formation when measured by imaging techniques like DEXA and pQCT.
Appetite Effects: Studies suggest Ipamorelin’s activity at ghrelin receptors may increase appetite and body weight in some models, potentially affecting fat pad weights and leptin levels.
This peptide blend is available for research and laboratory purposes only. Please review and adhere to the site’s Terms and Conditions before ordering.
